https://www.obipharma.com/investor-overview/information-security/ 2025-11-17T14:01:55+08:00 https://www.obipharma.com/what-we-do/expanded-access/ 2025-05-08T17:58:58+08:00 https://www.obipharma.com/what-we-do/technology-platform/ 2025-12-01T16:29:10+08:00 https://www.obipharma.com/what-we-do/pipeline-overview/ 2026-03-18T16:38:18+08:00 https://www.obipharma.com/what-we-do/ 2025-10-20T15:37:59+08:00 https://www.obipharma.com/sustainability/strategy-goals/ 2024-09-20T10:56:26+08:00 https://www.obipharma.com/sustainability/organization-operations/ 2025-08-22T11:29:04+08:00 https://www.obipharma.com/sustainability/stakeholder-dialog/ 2025-08-20T11:52:19+08:00 https://www.obipharma.com/sustainability/materiality-assessment/ 2025-08-21T14:06:54+08:00 https://www.obipharma.com/sustainability/latest-focus-topics/ 2025-08-21T14:23:28+08:00 https://www.obipharma.com/sustainability/archive-reports/ 2024-09-11T16:51:47+08:00 https://www.obipharma.com/investor-overview/dividend-policy/ 2025-07-21T14:17:03+08:00 https://www.obipharma.com/investor-overview/special-committees/ 2026-03-11T10:24:17+08:00 https://www.obipharma.com/investor-overview/shareholding-structure/ 2025-07-21T14:45:09+08:00 https://www.obipharma.com/investor-overview/internal-audits/ 2024-10-16T17:35:20+08:00 https://www.obipharma.com/investor-overview/integrity/ 2025-09-17T16:57:05+08:00 https://www.obipharma.com/investor-overview/governance-documents/ 2026-01-07T15:04:56+08:00 https://www.obipharma.com/investor-overview/corporate-overview/ 2024-09-11T12:09:20+08:00 https://www.obipharma.com/investor-overview/governance-board-of-directors/ 2025-11-19T17:44:19+08:00 https://www.obipharma.com/default-page/ 2024-05-28T09:18:03+08:00 https://www.obipharma.com/whats-new/ 2026-03-20T13:44:20+08:00 https://www.obipharma.com/people-and-culture/ 2025-11-20T17:23:03+08:00 https://www.obipharma.com/who-we-are/ 2026-03-23T10:47:55+08:00 https://www.obipharma.com/investor-overview/stock-quote/ 2024-09-09T15:46:07+08:00 https://www.obipharma.com/investor-overview/financial-report/ 2024-09-09T15:49:47+08:00 https://www.obipharma.com/investor-overview/annual-reports/ 2025-06-06T14:50:31+08:00 https://www.obipharma.com/publication-library/ 2024-05-29T16:46:43+08:00 https://www.obipharma.com/investor-overview/ir-presentation/ 2025-10-20T12:02:03+08:00 https://www.obipharma.com/news/ 2025-12-22T17:35:45+08:00 https://www.obipharma.com/sustainability/stakeholder-interaction/ 2025-09-16T14:57:32+08:00 https://www.obipharma.com/investor-overview/ 2025-12-31T15:52:40+08:00 https://www.obipharma.com/investor-overview/monthly-revenue/ 2024-09-12T09:34:48+08:00 https://www.obipharma.com/events/ 2024-12-02T19:14:06+08:00 https://www.obipharma.com/announcements/ 2024-05-30T19:15:57+08:00 https://www.obipharma.com/company-profile/ 2024-05-30T15:17:14+08:00 https://www.obipharma.com/sustainability/ 2025-08-22T11:41:02+08:00 https://www.obipharma.com/careers/ 2024-05-30T14:40:33+08:00 https://www.obipharma.com/contact/ 2025-09-01T09:56:33+08:00 https://www.obipharma.com/what-we-do/globo-h/ 2025-05-09T08:23:50+08:00 https://www.obipharma.com/who-we-are/leadership-team/ 2026-04-01T16:55:46+08:00 https://www.obipharma.com/privacy-policy/ 2024-10-24T13:46:41+08:00 https://www.obipharma.com/ 2026-03-20T14:06:11+08:00 https://www.obipharma.com/news/bio-europe-spring/ 2026-04-02T13:53:52+08:00 https://www.obipharma.com/news/arbitral-award-in-contract-dispute/ 2026-04-01T22:12:48+08:00 https://www.obipharma.com/news/obi-invited-to-speak-at-biologics-world-taiwan/ 2026-03-26T15:41:02+08:00 https://www.obipharma.com/news/obi-is-awarded-abea-2026/ 2026-03-12T15:00:21+08:00 https://www.obipharma.com/news/obi-receives-acceptance-of-ten-abstracts-at-2026aacr/ 2026-03-03T11:29:10+08:00 https://www.obipharma.com/news/obi-presents-next-generation-bispecific-dual-payload-adc-development-at-world-adc-london-2026/ 2026-02-25T08:14:54+08:00 https://www.obipharma.com/news/obi-and-tegmine-sign-exclusive-global-license-agreement/ 2026-01-12T20:03:42+08:00 https://www.obipharma.com/news/obi-investors-meeting-highlights-value-transformation-driven-by-adc-innovation/ 2025-12-19T11:49:00+08:00 https://www.obipharma.com/news/obi-201-at-sabcs-2025/ 2025-12-09T15:25:48+08:00 https://www.obipharma.com/news/obi-902-receives-consecutive-fda-odd/ 2025-12-05T15:19:42+08:00 https://www.obipharma.com/news/obi-902-has-been-granted-by-us-fda-for-odd/ 2025-11-17T14:39:01+08:00 https://www.obipharma.com/news/obi-volunteers-actively-participated-in-tbca/ 2025-10-21T11:03:30+08:00 https://www.obipharma.com/news/obi-chairman-dr-kung-yee-liang-receives-the-20242025-presidential-science-prize/ 2025-10-08T17:16:52+08:00 https://www.obipharma.com/news/biologics-world-korea-2025/ 2025-10-01T10:19:38+08:00 https://www.obipharma.com/news/obi-pharma-and-ap-biosciences-sign-technology-collaboration-agreement/ 2025-09-03T15:02:38+08:00 https://www.obipharma.com/news/obi-pharma-inc-announces-board-resolution-for-capital-reduction-to-offset-accumulated-losses/ 2025-09-01T16:58:35+08:00 https://www.obipharma.com/news/obi-pharma-announces-phase-1-2-study-initiation-for-obi-902/ 2025-09-02T15:16:17+08:00 https://www.obipharma.com/news/obi-pharma-showcases-innovative-pipeline-platforms-and-technologies-at-bio-asia-taiwan-2025/ 2025-08-06T09:20:00+08:00 https://www.obipharma.com/news/obi-pharma-adc-strategy-pivot/ 2025-08-06T09:53:31+08:00 https://www.obipharma.com/news/2025-world-adc-asia-summit/ 2025-08-06T15:56:27+08:00 https://www.obipharma.com/news/obi-pharma-enters-adc-collaboration-with-tegmine-therapeutics/ 2025-06-06T15:22:37+08:00 https://www.obipharma.com/news/obi-pharma-announces-u-s-fda-clearance-of-ind-application-for-a-phase-1-2-study-of-obi-902/ 2025-05-01T08:26:30+08:00 https://www.obipharma.com/news/obi-pharma-unveils-new-thiobi-and-hyprobi-platforms/ 2025-04-29T10:50:04+08:00 https://www.obipharma.com/news/obi-822-completes-second-interim-analysis-of-phase-iii-trial-obi-announces-trial-termination-refocuses-resources-on-adc-development/ 2025-04-23T19:15:11+08:00 https://www.obipharma.com/news/obi-pharma-announces-poster-presentations-at-the-aacr-2025-annual-meeting/ 2025-04-23T08:51:12+08:00 https://www.obipharma.com/news/glycobi-advances-bispecific-and-dual-payload-adc-development/ 2025-03-28T15:05:00+08:00 https://www.obipharma.com/news/obi-wins-most-promising-immunotherapy-pipeline-award/ 2025-03-26T18:37:54+08:00 https://www.obipharma.com/news/new-chairman-of-obigen-pharma-obi-pharma-ceo-heidi-wang-takes-over/ 2025-03-18T14:26:41+08:00 https://www.obipharma.com/news/obi-pharma-receives-most-promising-adc-clinical-candidate-in-taiwan-award-dr-heidi-wang-a/ 2025-03-12T19:08:20+08:00 https://www.obipharma.com/news/obi-pharma-invited-to-host-workshop-at-world-adc-london-sharing-adc-development-insights-and-unveiling-linker-technology-details-for-the-first-time/ 2025-03-04T14:26:52+08:00 https://www.obipharma.com/news/obi-pharmas-glycobi-platform-gains-attention-at-nanjing-summit-optimized-process-design-and-cmc-key-to-next-generation-adc-development/ 2025-03-02T13:43:05+08:00 https://www.obipharma.com/news/obi-pharma-showcases-proprietary-adc-platform-glycobi-in-china/ 2025-02-21T10:26:31+08:00 https://www.obipharma.com/news/invited-to-the-2025-healthcare-conference-in-taipei/ 2025-02-19T15:13:36+08:00 https://www.obipharma.com/news/obi-pharmas-obi-992-research-paper-selected-as-a-first-disclosure-article-featured-in-molecular-cancer-therapeutics-journal/ 2025-12-09T15:02:13+08:00 https://www.obipharma.com/news/obi-pharma-enters-collaboration-with-glytech/ 2024-12-23T09:05:42+08:00 https://www.obipharma.com/news/obi-pharma-earns-sports-enterprise-certification-again/ 2024-12-11T18:58:53+08:00 https://www.obipharma.com/news/key-technologies-innovative-products-flexible-business-models-dr-heidi-wang-shaping-obi-pharma-into-a-leading-and-thriving-global-biotech-company/ 2024-12-02T17:38:26+08:00 https://www.obipharma.com/news/obi-pharma-showcases-biomarker-innovations-at-singapore-apac-summit/ 2024-12-02T10:23:45+08:00 https://www.obipharma.com/news/obi-992-ranks-among-world-adc-award-top-8-stands-strong-among-global-pharma-giants-despite-missing-top-prize-gains-global-rec/ 2024-11-26T15:36:49+08:00 https://www.obipharma.com/news/obi-pharma-invited-to-speak-at-world-adc-conference-innovative-linker-technology-and-glycobi-adc-platform-capture-global-attention/ 2024-11-06T16:38:19+08:00 https://www.obipharma.com/news/obi-pharma-to-showcase-research-achievements-and-cutting-edge-adc-platform-technology-frequent-speaking-engagements-at-prestigious-international-conferences/ 2024-11-26T15:35:36+08:00 https://www.obipharma.com/news/obi-pharma-and-fu-jen-catholic-university-sign-industry-academia-collaboration-mou-advancing-biotechnology-innovation-and-developing-young-talent/ 2024-11-26T15:37:36+08:00 https://www.obipharma.com/news/obi-volunteers-at-a-breast-cancer-patient-event-showcasing-our-commitment-to-patients-and-to-new-drug-development/ 2024-10-27T16:19:09+08:00 https://www.obipharma.com/news/ascentawits-pharma-announced-the-interim-analysis-results-of-the-ast-3424-phase-ii-clinical-efficacy-and-safety-study-in-advanced-hcc-at-the-2024-csco-conference/ 2024-10-13T17:02:35+08:00 https://www.obipharma.com/news/obi-992-shortlisted-as-the-most-promising-clinical-candidate-in-the-11th-annual-world-adc-awards/ 2024-09-26T11:53:01+08:00 https://www.obipharma.com/news/the-2nd-world-adc-linker-conjugation-summit-obi-pharma-presents-results-on-patented-enzyme-endosymeobi-for-adcs/ 2024-08-22T18:56:01+08:00 https://www.obipharma.com/news/obi-992-has-been-approved-by-us-fda-for-orphan-drug-designation-for-the-treatment-of-gastric-cancer/ 2024-08-12T17:22:26+08:00 https://www.obipharma.com/news/obi-pharma-an-exciting-launching-pad-for-young-scientists/ 2024-07-30T09:22:31+08:00 https://www.obipharma.com/news/obis-proprietary-adc-platform-glycobi-seeks-collaborative-partnerships-for-development/ 2024-07-29T09:26:26+08:00 https://www.obipharma.com/news/vision-obi-presents-a-five-year-strategic-plan/ 2024-07-26T15:00:38+08:00 https://www.obipharma.com/news/obi-shares-opportunities-and-challenges-of-adc-development-at-bioasia2024/ 2024-07-25T12:08:14+08:00 https://www.obipharma.com/news/obi-s-adc-technology-platform-glycobi-and-enzyme-endosymeobi-two-trademarks-approved-by-taiwan-intellectual-property-office/ 2024-09-27T09:19:53+08:00 https://www.obipharma.com/news/obi-pharma-shareholders-meeting-launches-new-company-strategy-and-embraces-transformation/ 2024-06-28T15:07:53+08:00 https://www.obipharma.com/news/obi-s-proprietary-enzyme-endosymeobi/ 2024-07-11T08:44:36+08:00 https://www.obipharma.com/news/the-golden-torch-award/ 2024-06-21T22:35:04+08:00 https://www.obipharma.com/news/obi-pharma-announces-phase-1-2-study-initiation-for-obi-992-a-trop2-targeted-antibody-drug-conjugate-adc-for-cancer-therapy/ 2024-06-12T17:25:41+08:00 https://www.obipharma.com/news/obi-pharma-at-bio-usa-2024/ 2024-06-07T17:02:10+08:00 https://www.obipharma.com/news/poster-presentations-at-the-aacr-2024-annual-meeting-for-obi-992-and-glycobi-adc-platform/ 2024-06-05T17:02:31+08:00 https://www.obipharma.com/news/obi-pharma-announces-poster-presentations-at-the-aacr-2024-annual-meeting-for-obi-992-and-glycobi-adc-platform/ 2024-05-28T15:11:23+08:00 https://www.obipharma.com/news/obi-pharma-to-present-the-study-results-of-obi-992-at-the-14th-world-adc-london/ 2024-05-28T15:13:55+08:00 https://www.obipharma.com/news/obi-announces-the-termination-of-obi-3424-phase-ii-trial/ 2024-05-28T15:14:00+08:00 https://www.obipharma.com/news/obi-pharma-announces-u-s-fda-clearance-of-ind-application-for-a-phase-1-2-study-of-obi-992/ 2024-05-28T15:14:05+08:00 https://www.obipharma.com/news/kung-yee-liang-ph-d-was-elected-as-the-chairman-of-obi-pharma-inc/ 2024-05-28T15:14:10+08:00 https://www.obipharma.com/news/obi-pharma-proprietary-adc-technology-platform-plug-and-play/ 2024-05-28T15:14:16+08:00 https://www.obipharma.com/news/obi-pharma-inc-achieves-iso-iec-27001-international-information-security-certification/ 2024-05-28T15:14:22+08:00 https://www.obipharma.com/news/obi-volunteers-on-a-mission/ 2024-05-28T15:14:32+08:00 https://www.obipharma.com/news/obi-pharma-announces-executive-leadership-management-change-heidi-wang-ph-d-appointed-as-chief-executive-officer/ 2024-05-28T15:14:43+08:00 https://www.obipharma.com/news/poster-presentations-at-aacr-2023-annual-meeting-for-obi-999-combination-synergy-with-checkpoint-inhibitor-as-well-as-globo-h-targeted-car-t-cell-immunotherapy/ 2024-05-28T15:15:11+08:00 https://www.obipharma.com/news/obi-pharma-announces-poster-presentations-at-aacr-2023-annual-meeting-for-obi-999-combination-synergy-with-checkpoint-inhibitor-as-well-as-globo-h-targeted-car-t-cell-immunotherapy/ 2024-05-28T15:15:17+08:00 https://www.obipharma.com/news/obi-pharma-announces-discontinuation-of-the-phase-1-2-study-of-its-antibody-obi-888-to-focus-on-other-priority-cancer-programs/ 2024-05-28T15:15:25+08:00 https://www.obipharma.com/news/poster-presentations-at-the-2022-asco-annual-meeting-for-adagloxad-simolenin-obi-999-and-obi-3424/ 2024-05-28T15:15:29+08:00 https://www.obipharma.com/news/obi-pharma-announces-poster-presentations-at-the-2022-asco-annual-meeting-for-adagloxad-simolenin-obi-999-obi-3424-and-exhibit-booth/ 2024-05-28T15:15:34+08:00 https://www.obipharma.com/news/poster-presentations-at-aacr-2022-annual-meeting-for-obi-3424-and-globo-h-science/ 2024-05-28T15:15:37+08:00 https://www.obipharma.com/news/obi-pharma-announces-poster-presentations-at-aacr-2022-annual-meeting-for-obi-3424-and-globo-h-science/ 2024-05-28T15:15:41+08:00 https://www.obipharma.com/news/obi-pharma-enters-license-agreement-with-odeon-therapeutics-for-the-rights-of-obi-999-and-obi-833-in-china-hong-kong-and-macau/ 2024-05-28T15:15:46+08:00 https://www.obipharma.com/news/obi-pharma-announces-its-in-house-covid-19-vaccine-bcvax-can-induce-potent-antibodies-to-neutralize-against-all-variants/ 2024-05-28T15:15:50+08:00 https://www.obipharma.com/news/obi-pharma-announces-phase-2-studies-patient-enrollment-for-obi-999-and-obi-3424/ 2024-05-28T15:17:55+08:00 https://www.obipharma.com/news/obi-pharma-announces-first-cancer-patient-enrolled-on-obi-999-in-phase-2-study/ 2024-05-28T15:18:48+08:00 https://www.obipharma.com/news/obi-pharma-announces-first-patient-enrolled-on-swog-cancer-research-networks-obi-3424-phase-1-2-study-targeting-akr1c3-in-t-all-and-t-lbl/ 2024-05-28T15:18:52+08:00 https://www.obipharma.com/news/poster-presentations-at-aacr-2021-annual-meeting-for-obi-3424-obi-998-globo-h-and-ssea-4/ 2024-05-28T15:18:56+08:00 https://www.obipharma.com/news/obi-pharma-announces-poster-presentations-at-aacr-2021-annual-meeting-for-obi-3424-obi-998-globo-h-and-ssea-4/ 2024-05-28T15:18:59+08:00 https://www.obipharma.com/news/obi-pharma-inc-to-present-at-the-39th-j-p-morgan-healthcare-conference/ 2024-05-28T15:19:30+08:00 https://www.obipharma.com/news/esmo-asia-2020-virtual-annual-meeting-for-obi-833-a-novel-anti-globo-h-targeted-therapeutic-cancer-vaccine/ 2024-05-28T15:21:18+08:00 https://www.obipharma.com/news/obi-pharma-announces-presentations-at-esmo-asia-2020-virtual-annual-meeting-for-obi-833-a-novel-anti-globo-h-targeted-therapeutic-cancer-vaccine/ 2024-05-28T15:19:44+08:00 https://www.obipharma.com/news/obi-pharma-announces-obi-999-presentation-at-2020-world-adc-digital-meeting/ 2024-05-28T15:21:22+08:00 https://www.obipharma.com/news/poster-presentations-at-aacr-2020-virtual-annual-meeting-ii/ 2024-05-28T15:21:26+08:00 https://www.obipharma.com/news/obi-pharma-announces-poster-presentations-at-aacr-2020-virtual-annual-meeting-ii/ 2024-05-28T15:21:30+08:00 https://www.obipharma.com/news/obi-pharma-posters-at-2020-asco-virtual-annual-meeting-for-adagloxad-simolenin-obi-999-and-obi-3424/ 2024-05-28T15:21:34+08:00 https://www.obipharma.com/news/obi-pharma-announces-poster-presentations-at-2020-asco-virtual-annual-meeting-for-adagloxad-simolenin-obi-999-and-obi-3424/ 2024-05-28T15:21:38+08:00 https://www.obipharma.com/news/obi-pharma-updates-on-clinical-trial-activities-during-covid-19-pandemic/ 2024-05-28T15:21:42+08:00 https://www.obipharma.com/news/obi-pharma-granted-u-s-fda-orphan-drug-designation-for-the-treatment-of-gastric-cancer-for-its-antibody-drug-conjugate-adc-targeted-cancer-therapy-obi-999/ 2024-05-28T15:21:45+08:00 https://www.obipharma.com/news/obi-pharma-inc-to-present-at-the-j-p-morgan-healthcare-conference-3/ 2024-05-28T15:21:49+08:00 https://www.obipharma.com/news/obi-pharma-granted-fda-orphan-drug-designation-for-the-treatment-of-pancreatic-cancer-for-its-antibody-drug-conjugate-adc-targeted-cancer-therapy-obi-999/ 2024-05-28T15:21:52+08:00 https://www.obipharma.com/news/obi-pharma-announces-initiation-of-a-phase-1-2-study-of-its-antibody-drug-conjugate-adc-targeted-cancer-therapy-obi-999/ 2024-05-28T15:21:56+08:00 https://www.obipharma.com/news/obi-pharma-announces-u-s-fda-clearance-of-ind-application-for-a-phase-1-2-study-of-its-antibody-drug-conjugate-adc-targeted-cancer-therapy-obi-999/ 2024-05-28T15:21:59+08:00 https://www.obipharma.com/news/obi-pharma-announces-poster-presentations-at-aacr-2019-for-novel-globo-h-immuno-oncology-therapeutics-obi-888-and-obi-999/ 2024-05-28T15:22:02+08:00 https://www.obipharma.com/news/new-scientific-research-provides-link-between-globo-series-glycosphingolipids-gsls-antigens-and-tumor-survival-in-breast-cancer/ 2024-05-28T15:22:05+08:00 https://www.obipharma.com/news/obi-pharma-inc-to-present-at-the-j-p-morgan-healthcare-conference/ 2024-05-28T15:22:40+08:00 https://www.obipharma.com/news/obi-pharma-granted-fda-orphan-drug-designation-for-obi-888-for-the-treatment-of-pancreatic-cancer/ 2024-05-28T15:22:51+08:00 https://www.obipharma.com/news/obi-pharma-granted-fda-orphan-drug-designation-for-obi-3424-for-the-treatment-of-acute-lymphoblastic-leukemia-all/ 2024-05-28T15:22:56+08:00 https://www.obipharma.com/news/obi-pharma-granted-fda-orphan-drug-designation-for-obi-3424-for-the-treatment-of-hepatocellular-carcinoma-hcc/ 2024-05-28T15:23:00+08:00 https://www.obipharma.com/news/obi-pharma-announces-fda-clearance-of-obi-3424-ind-application-for-a-phase-i-ii-study-targeting-akr1c3-solid-tumors/ 2024-05-28T15:23:05+08:00 https://www.obipharma.com/news/obi-pharma-announces-fda-clearance-of-ind-application-for-a-phase-1-study-of-a-monoclonal-antibody-cancer-immunotherapy-obi-888/ 2024-05-28T15:23:11+08:00 https://www.obipharma.com/news/obi-pharma-announces-participation-at-the-36th-j-p-morgan-annual-healthcare-conference-in-san-francisco-from-january-8-10-2018/ 2024-05-28T15:23:16+08:00 https://www.obipharma.com/news/obi-pharma-announces-obi-3424-results-from-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/ 2024-05-28T15:23:21+08:00 https://www.obipharma.com/news/obi-pharma-announces-presentation-on-obi-3424-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/ 2024-05-28T15:23:25+08:00 https://www.obipharma.com/news/licensing-agreement-of-thiobridge-signed-with-abzena-aim-abza/ 2024-05-28T15:23:31+08:00 https://www.obipharma.com/news/obi-pharma-announces-acquisition-of-th-3424-from-threshold-pharmaceuticals/ 2024-05-28T15:23:35+08:00 https://www.obipharma.com/news/china-fda-approves-clinical-trial-application-for-adagloxad-simolenin-phase-iii-study/ 2024-05-28T15:23:43+08:00 https://www.obipharma.com/news/obi-pharma-holds-eop2-meeting-with-us-fda/ 2024-05-28T15:23:49+08:00 https://www.obipharma.com/news/obi-pharma-deeply-disappointed-with-prosecutors-decision-to-proceed-with-cases-facts-should-demonstrate-innocence/ 2024-05-28T15:23:55+08:00 https://www.obipharma.com/news/obi-pharma-awarded-level-a-recognition-for-tips-management/ 2024-05-28T15:24:01+08:00 https://www.obipharma.com/news/obi-pharma-granted-obi-833-patents-for-taiwan-and-australia/ 2024-05-28T15:24:06+08:00 https://www.obipharma.com/news/obi-pharma-sponsors-successful-adagloxad-simolenin-obi-822-symposium-at-esmo/ 2024-05-28T15:24:16+08:00 https://www.obipharma.com/news/legal-statement-obis-attorneys-decide-to-take-further-actions-against-next-magazine/ 2024-05-28T15:24:27+08:00 https://www.obipharma.com/news/obi-pharma-to-sponsor-adagloxad-simolenin-satellite-symposium-at-the-2016-esmo-annual-meeting/ 2024-05-28T15:24:33+08:00 https://www.obipharma.com/news/michael-chang-the-u-s-department-of-justice-had-already-proven-my-innocence/ 2024-05-28T15:24:40+08:00 https://www.obipharma.com/news/dr-nathan-chen-leaves-obi-pharma-accepts-new-role-on-companys-medical-advisory-board/ 2024-05-28T15:25:09+08:00 https://www.obipharma.com/news/quick-takes-on-promising-new-approaches-to-treating-breast-cancer/ 2024-05-28T15:25:14+08:00 https://www.obipharma.com/news/asco-kol-interviews-dr-hope-rugo%ef%bc%8fdr-james-c-paulson/ 2024-05-28T15:25:19+08:00 https://www.obipharma.com/news/obi-pharma-presents-data-for-novel-investigational-obi-822-obi-821-in-patients-with-metastatic-breast-cancer-at-the-2016-american-society-of-clinical-oncology-annual-meeting/ 2024-05-28T15:25:24+08:00 https://www.obipharma.com/news/obis-abstract-at-asco-2016-randomized-phase-2-3-trial-of-active-immunotherapy-with-opt-822-opt-821-in-patients-with-metastatic-breast-cancer/ 2024-05-28T15:25:28+08:00 https://www.obipharma.com/news/obi-pharma-to-present-new-data-at-the-2016-american-society-of-clinical-oncology-asco-annual-meeting/ 2024-05-28T15:25:32+08:00 https://www.obipharma.com/news/company-position-statement-regarding-recent-investigation-of-senior-executives/ 2024-05-28T15:25:36+08:00 https://www.obipharma.com/news/obi-pharma-announces-decision-by-asco-to-accept-its-abstract-for-oral-presentation-at-ascos-2016-annual-meeting/ 2024-05-28T15:25:41+08:00 https://www.obipharma.com/news/obi-pharma-reports-topline-results-from-obi-822-821-randomized-controlled-phase-2-3-clinical-trial-in-patients-with-metastatic-breast-cancer/ 2024-05-28T15:25:45+08:00 https://www.obipharma.com/news/obi-pharma-enters-exclusive-agreement-with-msd-for-rights-to-dificid-fidaxomicin-in-taiwan/ 2024-05-28T15:25:50+08:00 https://www.obipharma.com/news/obi-pharma-to-unblind-its-phase-2-3-clinical-trial-of-obi-822-active-immunotherapy-for-metastatic-breast-cancer-by-march-2016/ 2024-05-28T15:25:58+08:00 https://www.obipharma.com/news/clarification-about-the-progressive-disease-pd-number-of-the-opt-822-001-clinical-trial-as-reported-in-the-taiwan-media-on-4-june-2015/ 2024-05-28T15:26:03+08:00 https://www.obipharma.com/news/cancer-active-immunotherapy-obi-822-mechanism-action/ 2024-05-28T15:26:49+08:00 https://www.obipharma.com/news/introduction-of-obi-pharma-inc-s/ 2024-05-28T15:28:27+08:00 https://www.obipharma.com/news/obi-pharma-announces-completion-of-patient-enrollment-in-phase-2-phase-3-clinical-trial-of-obi-822-active-immunotherapy-for-metastatic-breast-cancer/ 2024-05-28T15:26:58+08:00 https://www.obipharma.com/news/obi-pharma-inc-won-taiwan-venture-capital-star-the-best-investment-award/ 2024-05-28T15:27:13+08:00 https://www.obipharma.com/news/obi-pharma-announces-nt-1-5-billion-capital-infusion/ 2024-05-28T15:27:21+08:00 https://www.obipharma.com/news/obi-pharma-wins-the-greatest-potential-award-at-the-2013-outstanding-biotech-awards/ 2024-05-28T15:27:27+08:00 https://www.obipharma.com/news/obi-pharma-re-elects-its-board-of-directors-and-supervisors-and-selects-a-new-chairman-of-the-board/ 2024-05-28T15:27:34+08:00 https://www.obipharma.com/news/obi-pharma-to-launch-phase-1-clinical-trial-for-a-new-generation-of-carbohydrate-cancer-immunotherapy-in-2014/ 2024-05-28T15:27:40+08:00 https://www.obipharma.com/news/obis-company-english-name-official-renamed-obi-pharma-inc/ 2024-05-28T15:27:51+08:00 https://www.obipharma.com/news/breast-cancer-new-drug-obi-822-821-received-taiwan-fda-approval-for-entering-phase-iii-trial/ 2024-05-28T15:27:55+08:00 https://www.obipharma.com/news/dificid-fidaxomicin-approved-by-taiwan-department-of-health-for-the-treatment-of-cdad/ 2024-05-28T15:28:00+08:00 https://www.obipharma.com/announcement/announcement-of-the-final-award-of-the-rapid-arbitration-initiated-by-obi-in-delaware-usa-against-biosion/ 2026-04-01T14:49:12+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-not-distributing-dividends-of-2025/ 2026-03-24T15:27:21+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-the-bod-resolved-to-convene-the-2026-annual-general-shareholders-meeting/ 2026-03-24T15:23:04+08:00 https://www.obipharma.com/announcement/change-the-agent-for-stock-affairs/ 2026-03-10T14:42:36+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-convene-the-2026-annual-general-shareholders-meeting/ 2026-03-09T16:30:16+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-accumulated-losses-have-reached-one-half-of-paid-in-capital/ 2026-03-09T16:18:40+08:00 https://www.obipharma.com/announcement/announcement-of-not-distributing-dividends-in-2025/ 2026-03-09T16:14:44+08:00 https://www.obipharma.com/announcement/announcement-of-2025-consolidated-financial-statements-were-approved-by-the-board-of-directors/ 2026-03-09T16:09:36+08:00 https://www.obipharma.com/announcement/announcement-for-the-expected-date-of-the-board-of-directors-meeting-for-2025-financial-reports-is-2026-03-09/ 2026-02-26T14:38:50+08:00 https://www.obipharma.com/announcement/the-company-received-notice-from-swog-regarding-the-analysis-results-of-phase-ii-stage-1-clinical-trial-of-obi-3424-in-t-all-and-t-lbl/ 2026-02-04T18:16:51+08:00 https://www.obipharma.com/announcement/announcement-of-completion-of-the-companys-capital-change-registration-and-adjustment-to-the-share-replacement-plan/ 2025-12-31T15:26:58+08:00 https://www.obipharma.com/announcement/the-companys-bod-resolved-to-enter-into-commercial-licensing-agreement-with-tegmine-for-the-development-of-glycoprotein-monoclonal-antibody-adc/ 2025-12-19T15:05:53+08:00 https://www.obipharma.com/announcement/announcement-of-bods-resolution-to-lift-the-non-competition-restrictions-for-managerial-officer/ 2025-12-19T15:01:24+08:00 https://www.obipharma.com/announcement/announcement-pursuant-to-article-22-13-of-the-regulations-governing-loaning-of-funds-and-making-of-endorsements-guarantees-by-public-companies/ 2025-12-19T14:54:55+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-its-bod-has-elected-dr-heidi-wang-to-serve-as-chairperson-of-the-board-and-concurrently-as-general-manager/ 2025-12-17T14:35:49+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-the-resignation-of-director/ 2025-12-09T16:23:21+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-the-retirement-of-chairperson-of-the-board-and-general-manager/ 2025-12-09T16:18:34+08:00 https://www.obipharma.com/announcement/obi-receives-us-fda-orphan-drug-designation-for-obi-902-trop2-adc-for-the-treatment-of-gastric-cancer/ 2025-12-05T14:43:04+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-record-date-of-capital-reduction-record-date-of-share-replacement-and-related-operational-plan/ 2025-11-24T17:19:27+08:00 https://www.obipharma.com/announcement/obi-receives-us-fda-orphan-drug-designation-for-obi-902-trop2-adc-for-the-treatment-of-cholangiocarcinoma/ 2025-11-16T14:19:37+08:00 https://www.obipharma.com/announcement/obi-is-invited-to-present-the-current-development-status-of-its-products-and-technology-platforms-at-the-investor-conference-hosted-by-masterlink-2/ 2025-11-14T14:40:43+08:00 https://www.obipharma.com/announcement/announcement-of-bods-resolution-to-lift-the-non-competition-restrictions-for-managerial-officers-2/ 2025-11-10T16:20:19+08:00 https://www.obipharma.com/announcement/announcement-that-the-cumulative-reduction-of-shareholding-in-major-subsidiary-obigen-pharma-has-reached-more-than-10/ 2025-11-10T16:13:59+08:00 https://www.obipharma.com/announcement/announcement-of-change-in-the-companys-certified-public-accountant-due-to-internal-adjustment-of-the-accounting-firm/ 2025-11-10T16:07:40+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-third-quarter-of-2025-were-approved-by-the-board-of-directors/ 2025-11-10T16:02:56+08:00 https://www.obipharma.com/announcement/announcement-for-the-expected-date-of-the-board-of-directors-meeting-for-2025q3-consolidated-financial-report-is-2025-11-10/ 2025-10-31T18:53:18+08:00 https://www.obipharma.com/announcement/announcement-to-creditors-of-the-company-for-conducting-capital-reduction-to-make-up-for-losses/ 2025-10-20T16:23:39+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-important-resolutions-of-the-2025-first-extraordinary-general-shareholders-meeting/ 2025-10-20T16:20:35+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-it-obtains-the-internal-control-special-audit-report-by-cpa/ 2025-10-17T14:38:55+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigens-bod-to-resolve-the-reference-date-for-conversion-of-employee-stock-options-to-common-shares/ 2025-10-02T14:47:09+08:00 https://www.obipharma.com/announcement/press-conference-on-material-information-regarding-the-board-resolution-for-capital-reduction-to-offset-accumulated-losses/ 2025-09-01T17:02:42+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-conduct-a-capital-reduction-to-offset-accumulated-losses/ 2025-09-01T16:52:52+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-convene-the-2025-first-extraordinary-general-shareholders-meeting/ 2025-09-01T16:58:38+08:00 https://www.obipharma.com/announcement/obigen-obi-858-phase-2-positive-results/ 2025-08-27T08:59:03+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigentfda-approves-ind-application-for-two-pivotal-phase-iii-studies-of-obi-858/ 2025-08-22T15:32:09+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-second-quarter-of-2025-were-approved-by-the-board-of-directors/ 2025-08-11T14:47:37+08:00 https://www.obipharma.com/announcement/announcement-for-the-expected-date-of-the-board-of-directors-meeting-for-2025q2-consolidated-financial-report-is-2025-08-11/ 2025-07-31T17:28:01+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-pharma-of-the-bods-resolution-to-lift-the-non-competition-restrictions-for-ceo-2/ 2025-07-28T18:21:57+08:00 https://www.obipharma.com/announcement/obi-902-trop2-adc-has-been-granted-by-the-tfda-to-proceed-to-phase-i-ii-human-clinical-trial/ 2025-07-18T14:51:31+08:00 https://www.obipharma.com/announcement/announcement-of-1st-sustainable-development-committee-members/ 2025-06-27T17:41:58+08:00 https://www.obipharma.com/announcement/announcement-of-6th-remuneration-and-nomination-committee-members/ 2025-06-27T17:38:37+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-nominated-dr-kung-yee-liang-to-serve-as-the-chairperson-of-the-board-2/ 2025-06-27T17:31:16+08:00 https://www.obipharma.com/announcement/announcement-of-5th-audit-and-risk-management-committee-members/ 2025-06-27T17:34:35+08:00 https://www.obipharma.com/announcement/announcement-of-2025-annual-general-shareholders-meetings-resolution-to-lift-the-non-competition-restrictions-for-directors/ 2025-06-27T17:27:34+08:00 https://www.obipharma.com/announcement/announcement-of-re-election-of-directors-at-the-2025-annual-shareholders-meeting/ 2025-06-27T17:21:17+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-important-resolutions-of-the-2025-annual-general-shareholders-meeting/ 2025-06-27T17:15:36+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-it-has-submitted-the-application-of-its-two-pivotal-phase-3-studies-for-obi-858-to-tfda/ 2025-06-26T15:06:01+08:00 https://www.obipharma.com/announcement/obi-has-submitted-the-ind-application-of-a-phase-i-ii-human-clinical-trial-for-obi-902-trop2-adc-to-the-tfda/ 2025-06-23T14:34:08+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-important-resolutions-of-the-2025-annual-general-shareholders-meeting/ 2025-06-18T14:33:58+08:00 https://www.obipharma.com/announcement/obis-glycobi-has-attracted-an-international-collaborator-tegmine-therapeutics-for-the-co-development-of-novel-antibody-drug-conjugates/ 2025-06-06T14:36:52+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-resolution-to-lift-the-non-competition-restrictions-for-directors/ 2025-05-20T16:03:27+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-important-resolutions-of-2025-annual-shareholders-meeting-and-accumulated-losses-amounting-to-50-of-paid-in-capital/ 2025-05-20T15:58:20+08:00 https://www.obipharma.com/announcement/the-board-of-directors-resolved-to-issue-new-common-shares-by-private-placement/ 2025-05-16T17:08:33+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-convene-the-2025-annual-general-shareholders-meeting-additional-matters/ 2025-05-12T19:30:22+08:00 https://www.obipharma.com/announcement/the-bod-resolved-to-rename-the-audit-committee-to-the-audit-and-risk-management-committee/ 2025-05-12T19:26:05+08:00 https://www.obipharma.com/announcement/the-bod-resolved-to-rename-the-remuneration-committee-to-the-remuneration-and-nomination-committee/ 2025-05-12T19:21:44+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-first-quarter-of-2025-were-approved-by-the-board-of-directors/ 2025-05-12T18:58:17+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-its-institutional-director-changes-its-representative-2/ 2025-05-12T18:54:32+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-the-resignation-of-its-representative-of-institutional-director/ 2025-05-12T18:50:42+08:00 https://www.obipharma.com/announcement/announcement-of-change-of-chief-scientific-officer/ 2025-05-12T18:46:51+08:00 https://www.obipharma.com/announcement/obi-announces-obi-833-termination-and-refocuses-resources-on-adc-development/ 2025-05-12T18:43:21+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-not-distributing-dividends-of-2024/ 2025-05-06T14:44:00+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-the-bod-resolved-to-convene-the-2025-annual-general-shareholders-meeting/ 2025-05-06T14:38:13+08:00 https://www.obipharma.com/announcement/obi-902-trop2-adc-has-been-granted-by-us-fda-to-proceed-to-phase-i-ii-human-clinical-trial/ 2025-05-02T09:02:27+08:00 https://www.obipharma.com/announcement/announcement-for-the-expected-date-of-the-board-of-directors-meeting-for-2025q1-consolidated-financial-report-is-2025-05-12/ 2025-04-30T17:01:21+08:00 https://www.obipharma.com/announcement/to-announce-the-press-release-for-material-information-in-a-press-conference/ 2025-04-23T18:51:01+08:00 https://www.obipharma.com/announcement/obi-decided-to-terminate-obi-822-phase-3-study-based-on-dsmbs-recommendation-and-to-redirect-resources-towards-adcs-development/ 2025-04-23T18:46:20+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-establishment-of-the-remuneration-committee-and-appointment-of-the-first-term-members/ 2025-04-22T15:04:21+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-the-new-replacement-of-its-spokesperson-and-acting-spokesperson/ 2025-04-22T15:00:13+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-the-change-of-its-financial-and-accounting-officer-2/ 2025-04-22T14:55:16+08:00 https://www.obipharma.com/announcement/obi-has-submitted-the-ind-application-of-a-phase-i-ii-human-clinical-trial-for-obi-902-trop2-adc-to-the-us-fda/ 2025-04-01T16:28:31+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-it-has-achieved-the-objectives-of-interim-analysis-for-phase-2-clinical-trial-of-obi-858/ 2025-03-20T18:06:28+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-bod-resolved-to-apply-for-public-offering-and-listing-in-the-tpex-emerging-stock-board/ 2025-03-18T14:56:52+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-bod-resolved-to-complete-replacement-of-non-physical-stocks/ 2025-03-18T15:00:25+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-the-bod-resolved-to-convene-the-2025-annual-general-shareholders-meeting/ 2025-03-18T14:52:19+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-not-distributing-dividends-of-2024/ 2025-03-18T14:43:07+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-the-bods-resolution-to-lift-the-non-competition-restrictions-for-ceo/ 2025-03-18T14:46:40+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-bod-nominated-dr-heidi-wang-as-the-chairperson/ 2025-03-18T14:38:51+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-the-change-of-its-financial-and-accounting-officer/ 2025-03-10T17:47:06+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-the-resignation-of-chief-commercial-officer/ 2025-03-10T17:41:20+08:00 https://www.obipharma.com/announcement/announcement-of-not-distributing-dividends-in-2024/ 2025-03-10T16:03:17+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-its-institutional-director-changes-its-representative-2/ 2025-03-10T15:58:34+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-the-resignation-of-chairperson/ 2025-03-10T15:51:51+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-the-resignation-of-its-institutional-director-2/ 2025-03-10T15:46:18+08:00 https://www.obipharma.com/announcement/announcement-of-2024-consolidated-financial-statements-were-approved-by-the-board-of-directors/ 2025-03-10T15:39:22+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-convene-the-2025-annual-general-shareholders-meeting/ 2025-03-10T15:31:29+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amarans-bod-to-resolve-the-reference-date-for-conversion-of-employee-stock-options-to-common-shares/ 2025-02-26T15:46:23+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-the-bod-resolved-to-issue-2025-employee-stock-options-and-the-subscription-rules/ 2025-02-26T16:03:11+08:00 https://www.obipharma.com/announcement/announcement-for-the-expected-date-of-the-board-of-directors-meeting-for-2024-financial-reports-is-2025-03-10/ 2025-02-26T15:20:52+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-pharma-the-new-appointment-of-ceo/ 2025-02-18T14:38:24+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-pharma-of-the-bods-resolution-to-lift-the-non-competition-restrictions-for-ceo/ 2025-02-18T14:44:06+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-tfda-clears-obi-858s-ind-application-for-repeat-dose-phase-ii-safety-study/ 2025-01-22T15:34:27+08:00 https://www.obipharma.com/announcement/obi-completed-the-capital-reduction-registration-for-the-restricted-stock-awards-cancelled/ 2025-01-03T14:56:59+08:00 https://www.obipharma.com/announcement/obi-pharma-and-glytech-have-entered-into-a-glycobi-marketing-agreement-in-japan-and-a-material-transfer-agreement/ 2024-12-23T14:46:12+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-to-acquire-the-worldwide-intellectual-property-rights-of-obi-858-and-sign-the-technology-transfer-agreement/ 2024-12-10T18:50:33+08:00 https://www.obipharma.com/announcement/obis-bod-resolved-to-transfer-the-worldwide-intellectual-property-rights-of-obi-858-and-sign-the-technology-transfer-agreement/ 2024-12-10T18:43:12+08:00 https://www.obipharma.com/announcement/the-companys-bod-resolved-the-redemption-and-cancellation-of-the-restricted-stock-awards-and-the-record-date-of-capital-reduction/ 2024-12-10T18:35:38+08:00 https://www.obipharma.com/announcement/announcement-of-the-expiration-of-the-companys-2024-cash-capital-increase-call-period-and-the-issuance-of-stocks/ 2024-12-06T17:19:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-it-has-filed-the-application-of-repeat-dose-phase-ii-safety-study-for-obi-858-to-tfda/ 2024-11-26T16:11:11+08:00 https://www.obipharma.com/announcement/obi-is-invited-to-present-the-current-development-status-of-its-products-and-technology-platforms-at-the-investor-conference-hosted-by-masterlink/ 2024-11-15T14:53:15+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-full-receipt-of-cash-capital-increase-in-2024-and-the-reference-date-of-capital-increase/ 2024-11-12T14:38:02+08:00 https://www.obipharma.com/announcement/subscription-rights-to-the-cash-issue-forfeited-by-directors-of-the-company-reaching-50-and-subscription-being-made-available-to-specific-persons-2/ 2024-11-05T18:12:58+08:00 https://www.obipharma.com/announcement/announcement-of-calls-on-unpaid-shares-of-2024-cash-capital-increase/ 2024-11-05T18:09:11+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-third-quarter-of-2024-were-approved-by-the-board-of-directors/ 2024-11-04T17:50:48+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-board-meeting-date-to-approve-2024q3-consolidated-financial-report/ 2024-10-25T11:22:20+08:00 https://www.obipharma.com/announcement/announcement-of-issue-price-and-banks-designated-to-collect-and-deposit-the-proceeds-for-2024-cash-capital-increase/ 2024-10-07T15:44:36+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-the-boards-resolution-to-lift-the-non-competition-restrictions-for-ceo/ 2024-09-26T16:03:13+08:00 https://www.obipharma.com/announcement/announcement-of-reference-date-of-cash-capital-increase-and-share-subscription/ 2024-09-26T15:38:12+08:00 https://www.obipharma.com/announcement/obi-receives-us-fda-orphan-drug-designation-for-obi-992-trop2-adc-for-the-treatment-of-gastric-cancer/ 2024-08-08T11:43:22+08:00 https://www.obipharma.com/announcement/announcement-of-change-of-accounting-officer/ 2024-08-05T15:03:56+08:00 https://www.obipharma.com/announcement/announcement-of-change-of-acting-spokesperson/ 2024-08-05T15:10:55+08:00 https://www.obipharma.com/announcement/announcement-of-new-appointment-of-chief-operating-officer/ 2024-08-05T15:27:53+08:00 https://www.obipharma.com/announcement/announcement-of-adjustment-of-an-item-in-the-plan-of-2018-cash-capital-increase/ 2024-08-05T15:39:23+08:00 https://www.obipharma.com/announcement/announcement-of-bods-resolution-to-issue-common-shares-through-cash-capital-increase-in-2024/ 2024-08-05T15:19:55+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-second-quarter-of-2024-were-approved-by-the-board-of-directors/ 2024-08-06T18:05:39+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-board-meeting-date-to-approve-2024q2-consolidated-financial-report/ 2024-08-05T15:40:05+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-the-companys-board-of-directors-resolved-to-appoint-mr-frank-chen-as-chairperson/ 2024-06-19T15:30:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-resolution-to-lift-the-non-competition-restrictions-for-new-directors/ 2024-06-19T15:27:00+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-re-election-of-directors-and-supervisors-at-the-2024-annual-general-shareholders-meeting/ 2024-06-19T15:23:24+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-important-resolutions-of-2024-annual-shareholders-meeting-and-accumulated-losses-amounting-to-50-of-paid-in-capital/ 2024-06-19T15:14:06+08:00 https://www.obipharma.com/announcement/announcement-of-2024-annual-general-shareholders-meetings-resolution-to-lift-the-non-competition-restrictions-for-directors/ 2024-06-17T17:06:58+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-important-resolutions-of-the-2024-annual-general-shareholders-meeting/ 2024-06-17T17:03:12+08:00 https://www.obipharma.com/announcement/obi-992-trop2-adc-has-been-granted-by-tfda-to-proceed-to-phase-i-ii-human-clinical-trial/ 2024-06-17T15:52:40+08:00 https://www.obipharma.com/announcement/obi-has-filed-the-application-of-a-phase-i-ii-human-clinical-trial-for-obi-992-trop2-adc-to-tfda/ 2024-05-31T11:28:05+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-the-companys-board-of-directors-resolved-to-appoint-ms-tessie-che-as-chairperson/ 2024-05-31T11:20:37+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-re-election-of-directors-and-supervisors-at-the-2024-annual-general-shareholders-meeting/ 2024-05-31T10:51:01+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-resolution-to-lift-the-non-competition-restrictions-for-new-directors/ 2024-05-31T10:54:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-important-resolutions-at-the-2024-annual-general-shareholders-meeting/ 2024-05-31T10:46:40+08:00 https://www.obipharma.com/announcement/obi-announces-the-termination-of-license-agreement-with-odeon-for-the-rights-of-obi-999-and-obi-833-in-china-hong-kong-and-macau/ 2024-05-31T10:35:58+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-first-quarter-of-2024-were-approved-by-the-board-of-directors/ 2024-05-31T10:32:24+08:00 https://www.obipharma.com/announcement/correct-consolidated-financial-reports-from-2023q1-to-q4-independent-2024q4-financial-report-and-ixbrl-which-have-no-impact-on-income-and-losses-and-net-assets/ 2024-05-31T10:27:04+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-tfda-clears-obi-858s-ind-application-for-phase-ii-human-clinical-trial/ 2024-05-31T10:20:44+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-board-meeting-date-to-approve-2024q1-consolidated-financial-report/ 2024-05-31T10:08:50+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-not-distributing-dividends-of-2023/ 2024-05-30T12:01:10+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-the-bod-resolved-to-convene-the-2024-annual-general-shareholders-meeting/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-not-distributing-dividends-of-2023/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-the-bod-resolved-to-issue-2024-employee-stock-options-and-the-subscription-rules/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-the-bod-resolved-to-convene-the-2024-annual-general-shareholders-meeting/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-bods-resolution-to-lift-the-non-competition-restrictions-for-managerial-officers/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-2023-consolidated-financial-statements-were-approved-by-the-board-of-directors/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-convene-the-2024-annual-general-shareholders-meeting/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-not-distributing-dividends-in-2023/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/obi-announces-the-termination-of-obi-3424-001-trial-while-continuing-the-collaboration-of-obi-3424-with-partners/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-it-has-filed-the-application-of-phase-ii-human-clinical-trial-for-obi-858-to-tfda/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/adagloxad-simolenin-obi-822-obi-821-receives-a-positive-1st-interim-analysis-recommendation-suggesting-the-continuation-of-the-phase-iii-tnbc-trial/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/obi-992-trop2-adc-has-been-granted-by-us-fda-to-proceed-to-phase-i-ii-human-clinical-trial/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-its-institutional-director-changes-its-representative/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-nominated-dr-kung-yee-liang-to-serve-as-the-chairperson-of-the-board/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-its-institutional-director-changes-its-representative/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-that-the-institutional-director-of-obi-sheng-cheng-investment-co-ltd-changes-its-representative-2/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-the-resignation-of-natural-person-director/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-the-resignation-of-its-institutional-director/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/obi-announces-termination-of-bcvax-obi-866-and-obi-999/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-resignation-of-the-chairperson/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/obi-licensed-the-worldwide-therapeutic-rights-of-obi-858-to-obigen/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-subsidiary-obigen-that-the-companys-board-appointed-internal-audit-officer/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/obi-has-filed-the-application-of-phase-i-ii-human-clinical-trial-for-obi-992-trop2-adc-to-us-fda/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/obi-is-invited-to-attend-the-investor-conference-hosted-by-masterlink-securities-and-declare-the-development-of-all-its-products-and-future-plan/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-change-of-the-companys-business-address-was-approved-by-the-board-of-directors/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-change-of-internal-audit-officer/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-change-of-financial-officer/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-third-quarter-of-2023-were-approved-by-the-board-of-directors/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-the-institutional-director-changes-its-representative/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-revise-2023-employee-stock-option-issuance-and-subscription-rules-2/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-second-quarter-of-2023-were-approved-by-the-board-of-directors/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/obi-licensed-nectin-4-human-antibody-rights-from-ablexis-llc/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-revise-2023-employee-stock-option-issuance-and-subscription-rules/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-nominated-yun-yen-to-serve-as-the-chairman-of-the-board/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-that-the-institutional-director-of-obi-sheng-cheng-investment-co-ltd-changes-its-representative/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-2023-shareholders-meetings-resolution-to-lift-the-non-competition-restrictions-for-directors/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-important-resolutions-of-the-2023-annual-shareholders-meeting/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-by-election-of-the-director-at-the-2023-annual-shareholders-meeting/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-important-resolutions-of-the-2023-annual-shareholders-meeting/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigens-resolution-to-lift-the-non-competition-restrictions-for-directors-at-2023-annual-shareholders-meeting/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-of-important-resolutions-of-the-2023-annual-shareholders-meeting/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-covid-19-vaccine-bcvax-has-been-granted-by-tfda-to-proceed-to-phase-i-clinical-trial/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-change-spokesperson/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-change-of-ceo/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-that-the-bod-resolved-to-issue-2023-employee-stock-options-and-the-subscription-rules/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-obigen-to-change-its-financial-and-accounting-officer/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-bod-resolved-to-amend-the-plan-to-disperse-shareholding-of-obigen-new-shareholding-dispersal-method/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-bod-resolved-to-amend-the-plan-to-disperse-shareholding-of-ap-biosciences-new-shareholding-dispersal-method/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-issue-2023-employee-stock-options-and-the-subscription-rules/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-convene-the-2023-annual-general-shareholders-meeting-new-approval/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-first-quarter-of-2023-were-approved-by-the-board-of-directors/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-not-distributing-dividends-of-2022/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-the-bod-resolved-to-convene-the-2023-annual-general-shareholders-meeting/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/obi-is-invited-to-attend-the-13th-taiwan-ceo-week-taiwan-new-economy-day-investor-meeting-on-air-held-by-qic/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/obi-has-filed-the-application-of-phase-i-human-clinical-trial-for-covid-19-vaccine-bcvax-to-tfda/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/update-the-related-information-regarding-the-leased-office-space-in-taipei-bioinnovation-park/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-not-distributing-dividends-in-2022/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-bod-resolved-the-plan-to-disperse-shareholding-of-obigen-pharma-inc/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-for-the-appointment-of-corporate-governance-officer-of-the-company/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-bod-resolved-the-plan-to-disperse-shareholding-of-ap-biosciences/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-convene-the-2023-annual-general-shareholders-meeting/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-2022-consolidated-financial-statements-were-approved-by-the-board-of-directors/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/%e4%bb%a3%e9%87%8d%e8%a6%81%e5%ad%90%e5%85%ac%e5%8f%b8%e5%9c%93%e7%a5%a5%e7%94%9f%e6%8a%80%e8%82%a1%e4%bb%bd%e6%9c%89%e9%99%90%e5%85%ac%e5%8f%b8%e5%85%ac%e5%91%8a%e8%91%a3%e4%ba%8b%e6%9c%83%e6%b1%ba-2/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/%e4%bb%a3%e9%87%8d%e8%a6%81%e5%ad%90%e5%85%ac%e5%8f%b8%e5%9c%93%e7%a5%a5%e7%94%9f%e6%8a%80%e8%82%a1%e4%bb%bd%e6%9c%89%e9%99%90%e5%85%ac%e5%8f%b8%e5%85%ac%e5%91%8a%e8%91%a3%e4%ba%8b%e6%9c%83%e6%b1%ba/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/the-first-in-class-novel-prodrug-obi-3424-has-been-granted-by-tfda-to-proceed-to-phase-ii-clinical-trial/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/%e6%9c%ac%e5%85%ac%e5%8f%b8%e5%89%8d%e9%a9%85%e5%9e%8b%e5%8c%96%e7%99%82%e6%96%b0%e8%97%a5obi-3424%e5%90%91%e5%8f%b0%e7%81%a3%e8%a1%9b%e7%a6%8f%e9%83%a8%e9%a3%9f%e8%97%a5%e7%bd%b2%e6%8f%90%e5%87%ba/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-that-application-for-phase-i-human-clinical-trial-of-bispecific-antibody-ap505-has-been-granted-by-us-fda/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-bods-resolution-to-lift-the-non-competition-restrictions-for-new-ceo/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/%e5%85%ac%e5%91%8a%e6%9c%ac%e5%85%ac%e5%8f%b8%e5%9f%b7%e8%a1%8c%e9%95%b7%e7%95%b0%e5%8b%95/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-change-of-the-spokesperson/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/%e5%85%ac%e5%91%8a%e6%9c%ac%e5%85%ac%e5%8f%b8%e8%91%a3%e4%ba%8b%e9%95%b7%e7%95%b0%e5%8b%95/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-death-of-chairman-of-the-board-supplementary-statement-on-the-circumstances-of-his-deputy/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/announcement-of-change-of-director/ 2024-04-26T14:36:15+08:00 https://www.obipharma.com/announcement/%e5%85%ac%e5%91%8a%e6%9c%ac%e5%85%ac%e5%8f%b8%e8%91%a3%e4%ba%8b%e9%95%b7%e9%80%9d%e4%b8%96/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/obi-866-immunogenic-therapeutic-glycan/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-to-file-application-for-phase-i-human-clinical-trial-of-bispecific-antibody-ap505-to-us-fda/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-that-it-obtains-the-internal-control-special-audit-report-by-cpa/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/amendments-to-related-matters-that-obi-forfeits-part-of-subscription-rights-of-obigens-cash-capital-increase-and-distributes-the-rights-to-its-shareholders/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/obi-sets-target-date-of-distribution-of-other-benefits-from-forfeiture-of-subscription-rights-to-its-shareholders-for-obigens-2022-cash-capital-increase/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/the-companys-bod-resolved-to-forfeit-part-of-subscription-rights-of-obigens-cash-capital-increase-and-distribute-the-rights-to-its-shareholders/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/the-company-correct-the-information-on-monetary-loans-extended-to-others-filed-on-september-and-october-2022/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-that-application-for-phase-i-human-clinical-trial-of-bispecific-antibody-ap203-has-been-granted-by-tfda/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-apbios-resolution-to-lift-non-competition-restrictions-for-directors-at-2022-extraordinary-shareholders-meeting/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-regarding-its-by-election-of-director-and-supervisor-at-2022-first-extraordinary-general-shareholders-meeting/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-important-resolutions-of-2022-first-extraordinary-general-shareholders-meeting/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-third-quarter-of-2022-were-approved-by-the-board-of-directors/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/the-chairman-decided-the-record-date-of-2022-first-issuance-of-rsu-according-to-the-resolution-of-bod/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-that-the-bod-resolved-to-convene-2022-first-extraordinary-general-shareholders-meeting/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/obi-822-cancer-immunotherapy-by-immune-activation-or-immune-modulation-via-globo-series-antigens-was-granted-by-uspto/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-of-the-resignation-of-its-institutional-director/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-investor-conference-hosted-by-masterlink-securities-3-2/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-of-ap-biosciences-full-receipt-of-cash-capital-increase-in-2022-and-the-reference-date-of-capital-increase/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-of-the-expiration-of-ap-biosciences-2022-cash-capital-increase-call-period/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-to-file-application-for-phase-i-human-clinical-trial-of-bispecific-antibody-ap203-to-tfda/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-that-application-for-phase-i-human-clinical-trial-of-bispecific-antibody-ap203-has-been-granted-by-us-fda/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-that-preemptive-rights-forfeited-by-all-directors-are-over-50-and-made-available-to-specific-persons/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-call-period-of-2022-cash-capital-increase/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-to-file-application-for-phase-i-human-clinical-trial-of-bispecific-antibody-ap203-to-us-fda/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-of-amendment-of-the-companys-2021-annual-report/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-that-preemptive-rights-forfeited-by-directors-are-over-50-and-made-available-to-specific-persons/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-that-the-cumulative-reduction-of-shareholding-in-major-subsidiary-ap-biosciences-has-reached-more-than-10/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/obi-forfeits-subscription-of-ap-biosciences-cash-capital-increase-distributes-rights-to-its-shareholders-and-sets-target-date/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/the-companys-bod-resolved-to-forfeit-the-subscription-of-ap-biosciences-cash-capital-increase-and-distribute-the-rights-to-its-shareholders/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/obis-bod-resolved-employees-and-amount-granted-for-the-first-issuance-of-rsu-and-authorized-the-decision-of-record-date-to-the-chairman/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-approved-the-amendment-of-2022-restricted-stock-awards-issuance-rules/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-second-quarter-of-2022-were-approved-by-the-board-of-directors/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-subsidiary-obigen-pharma-inc-that-bod-resolved-the-term-sheet-for-licensing-of-obi-858-in-china/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/supplementary-statements-on-news-article-4/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/the-company-announces-discontinuation-of-the-phase-ii-study-of-obi-888/ 2024-04-26T14:36:16+08:00 https://www.obipharma.com/announcement/announcement-of-the-status-of-implementation-of-the-commitments-during-the-up-listing-at-taipei-exchange/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-nominated-michael-chang-to-serve-as-the-chairman-of-the-board/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-of-2022-shareholders-meeting-resolution-to-lift-the-non-competition-restrictions-for-new-directors/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-of-5th-remuneration-committee-members/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-of-4th-audit-committee-members/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-of-re-election-of-directors-at-the-2022-annual-shareholders-meeting/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-important-resolutions-of-the-2022-annual-shareholders-meeting/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-of-the-bods-resolution-to-issue-common-shares-through-cash-capital-increase-and-the-reference-date/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-important-resolutions-of-the-2022-annual-shareholders-meeting/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-of-resolution-of-the-ex-rights-record-date-of-new-shares-through-capitalization-of-capital-surplus/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-ap-biosciences-of-important-resolutions-of-the-2022-annual-shareholders-meeting/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-rent-office-space-in-taipei-bioinnovation-park/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-approved-2022-restricted-stock-awards-and-the-issuance-rules/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-convene-the-2022-annual-general-shareholders-meeting-change-of-location-and-new-approval/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-first-quarter-of-2022-were-approved-by-the-board-of-directors/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-the-bod-resolved-to-revise-the-regulations-for-issuance-and-subscription-of-2020-employee-stock-options/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-of-not-distributing-dividends-of-2021/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-that-the-bod-resolved-to-convene-the-2022-annual-general-shareholders-meeting/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/obi-999-conjugated-biological-molecules-pharmaceutical-compositions-and-methods-was-granted-by-taiwan-intellectual-property-office/ 2024-04-26T14:36:17+08:00 https://www.obipharma.com/announcement/announcement-of-the-expiration-of-the-companys-2022-cash-capital-increase-call-period-and-the-issuance-of-stocks/ 2024-04-26T14:36:18+08:00 https://www.obipharma.com/announcement/aemps-of-spain-revokes-previous-approval-for-the-active-cancer-immunotherapy-obi-822-to-proceed-to-phase-iii-clinical-trial/ 2024-04-26T14:36:18+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-full-receipt-of-cash-capital-increase-in-2022-and-the-reference-date-of-capital-increase/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/announcement-of-not-distributing-dividends-in-2021/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-convene-the-2022-annual-general-shareholders-meeting/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/announcement-of-2021-consolidated-financial-statements-were-approved-by-the-board-of-directors/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/supplemental-announcement-subscription-rights-to-the-cash-issue-forfeited-by-directors-of-the-company-reaching-50-and-made-to-specific-persons/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/subscription-rights-to-the-cash-issue-forfeited-by-directors-of-the-company-reaching-50-and-subscription-being-made-available-to-specific-persons/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/announcement-of-calls-on-unpaid-shares-of-2022-cash-capital-increase/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/tfda-has-granted-the-approval-for-the-active-cancer-immunotherapy-obi-833-to-proceed-to-a-phase-ii-clinical-trial/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/supplementary-statements-on-news-article-3/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/announcement-of-acquisition-of-preferred-shares-of-odeon-therapeutics-cayman-limited/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/obi-enters-license-agreement-with-odeon-for-the-rights-of-obi-999-and-obi-833-in-china-hong-kong-and-macau/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/%e6%9c%ac%e5%85%ac%e5%8f%b8%e5%8f%97%e9%82%80%e5%8f%83%e5%8a%a0%e5%af%ac%e9%87%8f%e5%9c%8b%e9%9a%9b%e8%88%89%e8%be%a6%e4%b9%8b%e9%86%ab%e7%99%82%e4%bf%9d%e5%81%a5%e8%ab%96%e5%a3%87%e3%80%8cqic-healthc/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/announcement-of-issue-price-and-banks-designated-to-collect-and-deposit-the-proceeds/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/the-active-cancer-immunotherapy-obi-822-has-been-granted-by-anvisa-of-brazil-to-proceed-to-phase-iii-clinical-trial/ 2024-04-26T14:36:19+08:00 https://www.obipharma.com/announcement/supplementary-statements-on-news-article-2-2/ 2024-04-26T14:36:20+08:00 https://www.obipharma.com/announcement/announcement-of-preclinical-animal-study-results-of-obis-covid-19-vaccine/ 2024-04-26T14:36:20+08:00 https://www.obipharma.com/announcement/the-active-cancer-immunotherapy-obi-822-has-been-granted-by-urpl-of-poland-to-proceed-to-phase-iii-clinical-trial/ 2024-04-26T14:36:20+08:00 https://www.obipharma.com/announcement/announcement-of-reference-date-of-2022-cash-capital-increase-and-share-subscription/ 2024-04-26T14:36:21+08:00 https://www.obipharma.com/announcement/the-active-cancer-immunotherapy-obi-822-has-been-granted-by-aemps-of-spain-to-proceed-to-phase-iii-clinical-trial/ 2024-04-26T14:36:21+08:00 https://www.obipharma.com/announcement/the-active-cancer-immunotherapy-obi-822-has-been-granted-by-digemid-of-peru-to-proceed-to-phase-iii-clinical-trial/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/obi-has-filed-the-application-for-a-phase-ii-clinical-trial-for-obi-833-an-active-cancer-immunotherapy-to-tfda/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/obi-in-licensed-anti-trop2-antibody-exclusive-rights-from-biosion/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/the-active-cancer-immunotherapy-obi-822-has-been-granted-by-cofepris-of-mexico-to-proceed-to-phase-iii-human-clinical-study/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-subsidiary-obigen-that-obi-858-completes-its-phase-i-and-demonstrates-good-safety-proceeding-to-phase-ii-as-planned/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/obis-bod-resolved-to-in-license-a-preclinical-project-from-a-biotech-company-specialized-in-novel-cancer-therapies/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-of-the-resolution-of-the-board-of-directors-of-the-company-to-issue-common-shares-through-cash-capital-increase/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/supplementary-statements-on-news-article-2/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/intellectual-property-rights-licensing-of-obis-cancer-therapies-in-china-has-been-granted-by-moeaic/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-of-amendment-of-the-regulations-for-issuance-and-subscription-of-2021-employee-stock-options/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-third-quarter-of-2021-were-authorized-for-issuance-by-the-board-of-directors/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-investor-conference-hosted-by-masterlink-securities-2-2/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-major-subsidiary-amaran-biotechnology-inc-of-re-election-of-directors-and-supervisors-at-the-2021-annual-shareholders-meeting/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-major-subsidiary-amaran-biotechnology-inc-that-the-companys-board-of-directors-resolved-to-appoint-ms-tessie-che-as-chairperson/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-major-subsidiary-amaran-biotechnology-inc-of-resolution-to-lift-the-non-competition-restrictions-for-new-directors/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-major-subsidiary-amaran-biotechnology-inc-of-important-resolutions-of-the-2021-annual-shareholders-meeting/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/obi-866-immunogenic-therapeutic-glycan-compositions-and-uses-thereof-was-granted-by-taiwan-intellectual-property-office/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/application-of-investigational-device-exemption-for-immunohistochemistry-applied-to-phase-ii-clinical-trial-of-obi-999-has-been-granted-by-fda/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/the-globo-h-antibody-drug-conjugate-obi-999-has-been-granted-by-tfda-to-proceed-to-phase-ii-human-clinical-study/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/obi-has-filed-the-application-of-phase-ii-human-clinical-trial-for-globo-h-adc-obi-999-to-tfda-2/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/obi-filed-an-application-of-investigational-device-exemption-ide-for-phase-ii-cohort-expansion-human-clinical-trial-for-globo-h-antibody-drug-conjugate-obi-999-to-fda/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-biotechnology-inc-a-major-subsidiary-that-the-companys-board-of-directors-resolved-to-revise-the-regulations-for-issuance-and-subscription-of-2020-employe/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-amaran-biotechnology-inc-a-major-subsidiary-that-the-companys-board-of-directors-resolved-to-change-the-date-for-2021-annual-shareholders-meeting/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/supplementary-announcement-of-electronic-voting-shareholders-complimentary-gift-for-2021-annual-shareholders-meeting/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-issue-employee-stock-options-and-the-subscription-rules/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/new-appointment-of-audit-committee-member/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-of-the-consolidated-financial-statements-for-the-second-quarter-of-2021-were-authorized-for-issuance-by-the-board-of-directors/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/patent-of-obi-858-clostridium-botulinum-toxin-type-a-composition-formulation-and-use-thereof-was-granted-by-the-taiwan-intellectual-property-office/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-to-approve-the-lifting-of-non-competition-restrictions-for-directors-at-the-2021-annual-general-meeting/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-on-the-elected-independent-director-at-the-2021-annual-general-meeting/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-of-resolution-items-from-2021-annual-general-meeting/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/the-companys-board-of-directors-resolved-to-change-the-date-of-2021-shareholders-meeting-in-accordance-with-the-instructions-of-fsc/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/the-company-has-acquired-ordinary-shares-of-obigen-pharma-inc/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/the-company-will-postpone-the-annual-shareholders-meeting-to-june-21-2021-in-accordance-with-the-instructions-of-fsc-distribution-of-electronic-voting-shareholders-complimentary-gi/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/the-company-will-postpone-the-annual-shareholders-meeting-on-june-21-2021-in-accordance-with-the-instructions-of-fsc/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/supplementary-statement-for-2021-shareholders-meeting-change-of-location/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/obi-999-completes-its-phase-1-safety-evaluation-and-demonstrates-its-safety-with-no-major-concerns-proceeding-to-phase-2-as-planned/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/supplementary-statement-for-2021-shareholders-meeting-additional-matters/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-that-the-consolidated-financial-statements-for-the-first-quarter-of-2021-were-authorized-for-issuance-by-the-board-of-directors/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/updates-on-the-planned-allocation-of-the-cash-raised-from-the-2018-fundraising/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/the-active-cancer-immunotherapy-obi-822-adagloxad-simolenin-has-been-granted-by-south-african-health-products-regulatory-authority-sahpra-to-proceed-to-phase-iii-human-clinical-study/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/obi-833-completes-its-phase-1-cohort-expansion-study-proceeding-to-phase-2-as-planned/ 2024-04-26T14:36:22+08:00 https://www.obipharma.com/announcement/announcement-on-behalf-of-major-subsidiary-amaran-biotechnology-inc-that-the-company-s-board-of-directors-resolved-to-convene-the-2021-annual-general-shareholders-meeting/ 2024-04-26T14:36:23+08:00 https://www.obipharma.com/announcement/announcement-of-the-resolution-by-the-board-of-directors-not-to-distribute-dividends-by-the-company-on-behalf-of-major-subsidiary-amaran-biotechnology-inc/ 2024-04-26T14:36:23+08:00 https://www.obipharma.com/announcement/obi-3424-completes-its-phase-1-safety-evaluation-and-demonstrates-its-safety-with-no-major-concerns-proceeding-to-phase-2-as-planned/ 2024-04-26T14:36:23+08:00 https://www.obipharma.com/announcement/obi-filed-the-application-of-phase-iii-human-clinical-study-for-the-active-cancer-immunotherapy-obi-822-adagloxad-simolenin-to-the-health-authority-of-peru/ 2024-04-26T14:36:23+08:00 https://www.obipharma.com/announcement/obis-application-to-initiate-the-phase-iii-clinical-study-of-the-active-cancer-immunotherapy-obi-822-adagloxad-simolenin-has-been-denied-by-the-ministry-of-health-argentina/ 2024-04-26T14:36:24+08:00 https://www.obipharma.com/announcement/obi-filed-the-application-to-ema-for-phase-iii-human-clinical-study-of-the-active-cancer-immunotherapy-obi-822-adagloxad-simolenin-in-spain-german-and-poland/ 2024-04-26T14:36:24+08:00 https://www.obipharma.com/announcement/the-board-of-directors-resolved-to-hold-2021-annual-general-meeting/ 2024-04-26T14:36:24+08:00 https://www.obipharma.com/announcement/announcement-of-not-distributing-dividends-in-2020/ 2024-04-26T14:36:24+08:00 https://www.obipharma.com/announcement/announcement-of-2020-consolidated-financial-report/ 2024-04-26T14:36:24+08:00 https://www.obipharma.com/announcement/obi-filed-the-application-of-phase-iii-human-clinical-study-for-the-active-cancer-immunotherapy-obi-822-adagloxad-simolenin-to-the-drug-administrations-of-mexico/ 2024-04-26T14:36:24+08:00 https://www.obipharma.com/announcement/obi-licensed-obi-858-novel-botulinum-toxin-preparation-intellectual-property-right-of-global-aesthetic-medicine-to-obigen-pharma-inc/ 2024-04-26T14:36:25+08:00 https://www.obipharma.com/announcement/obi-filed-the-application-of-phase-iii-human-clinical-study-for-the-active-cancer-immunotherapy-obi-822-adagloxad-simolenin-to-the-drug-administrations-in-argentina-brazil-and-south-africa/ 2024-04-26T14:36:25+08:00 https://www.obipharma.com/announcement/mr-michael-chang-and-five-other-executives-received-an-acquittal-for-insider-trading-case-at-second-instance-by-taiwan-high-court/ 2024-04-26T14:36:26+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-the-39th-annual-j-p-morgan-healthcare-conference/ 2024-04-26T14:36:26+08:00 https://www.obipharma.com/announcement/obi-capital-increases-by-issuance-of-stocks-to-transfer-stocks-with-amaran-biotechnology-inc-announcement-of-base-day-and-trading-counterparty/ 2024-04-26T14:36:26+08:00 https://www.obipharma.com/announcement/the-active-cancer-immunotherapy-obi-822-adagloxad-simolenin-has-been-granted-by-national-medical-products-administration-nmpa-to-proceed-phase-iii-human-clinical-study/ 2024-04-26T14:36:26+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-investor-conference-hosted-by-masterlink-securities-3/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/obi-licensed-the-intellectual-property-right-of-global-aesthetic-medicine-to-a-designated-company/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/obi-capital-increases-by-issuance-of-stocks-to-transfer-stocks-with-amaran-biotechnology-inc-supplement-base-date/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/obi-received-the-reply-from-fda-about-the-investigational-device-exemption-ide-of-phase-i-ii-cohort-expansion-human-clinical-studies-for-first-in-class-novel-prodrug-obi-3424/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/announcement-of-2020-q3-financial-reports-submitted-to-the-board-of-directors/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/obi-capital-increases-by-issuance-of-stocks-to-transfer-stocks-with-amaran-biotechnology-inc-the-agreement-of-share-exchange-and-cooperation-signed-and-trading-counterparts-designated/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/obi-filed-an-application-of-investigational-device-exemption-ide-for-phase-i-ii-cohort-expansion-human-clinical-studies-for-first-in-class-novel-prodrug-obi-3424-to-fda/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/obi-capital-increases-by-issuance-of-stocks-as-the-consideration-of-share-exchange-cooperation-with-amaran-biotechnology-inc/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/announcement-of-press-release-of-press-conference-on-sept-28-2020/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/board-of-directors-resolved-to-license-dna-sequence-of-obi-888-to-ap-bioscience-inc-for-bispecific-antibody-development/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/board-of-directors-resolution-on-licensing-of-obi-833-obi-888-and-obi-999-in-china-including-hong-kong-and-macao/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/new-appointment-of-compensation-committee-member/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/tfda-clearance-for-phase-1-clinical-study-for-active-immunotherapeutic-cancer-vaccine-obi-866/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/tfda-clearance-for-phase-1-clinical-study-for-novel-botulinum-toxin-obi-858/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/announcement-on-the-change-of-representative-of-corporate-director/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/announcement-on-resignation-of-audit-committee-member/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/announcement-on-resignation-of-compensation-committee-member/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/announcement-on-resignation-of-independent-director/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/tfda-clearance-of-passive-immunotherapeutic-monoclonal-antibody-obi-888-for-phase-i-ii-human-clinical-studies/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/change-in-phase-iii-clinical-study-design-for-obi-822-targeting-tnbc-and-will-continue-the-study-with-new-clinical-study-design/ 2024-04-26T14:36:27+08:00 https://www.obipharma.com/announcement/resignation-of-representative-of-corporate-director/ 2024-04-26T14:36:28+08:00 https://www.obipharma.com/announcement/obi-filled-application-of-phase-1-human-clinical-study-for-active-immunotherapeutic-cancer-vaccine-obi-866-to-tfda/ 2024-04-26T14:36:28+08:00 https://www.obipharma.com/announcement/supplementary-statements-on-news-article/ 2024-04-26T14:36:28+08:00 https://www.obipharma.com/announcement/announcement-of-resolution-items-from-2020-annual-general-meeting/ 2024-04-26T14:36:28+08:00 https://www.obipharma.com/announcement/announcement-of-2020-annual-general-meeting-passes-removal-of-the-noncompete-clause-for-directors/ 2024-04-26T14:36:28+08:00 https://www.obipharma.com/announcement/obi-filled-application-of-phase-1-human-clinical-study-for-novel-botulinum-toxin-preparation-obi-858-to-tfda/ 2024-04-26T14:36:28+08:00 https://www.obipharma.com/announcement/obi-has-filed-application-of-phase-i-ii-human-clinical-studies-for-passive-immunotherapeutic-monoclonal-antibody-obi-888-to-tfda/ 2024-04-26T14:36:28+08:00 https://www.obipharma.com/announcement/obi-has-signed-a-non-binding-mou-to-form-a-strategic-partnership-to-develop-novel-bispecific-antibody-cancer-treatments/ 2024-04-26T14:36:29+08:00 https://www.obipharma.com/announcement/supplementary-statement-for-2020-shareholders-meeting-change-in-location-and-new-items/ 2024-04-26T14:36:29+08:00 https://www.obipharma.com/announcement/the-active-cancer-immunotherapy-obi-822-adagloxad-simolenin-has-been-granted-by-ministry-of-food-and-drug-safety-of-south-korea-to-proceed-phase-iii-human-clinical-study/ 2024-04-26T14:36:29+08:00 https://www.obipharma.com/announcement/due-to-the-tense-situation-of-novel-coronavirus-disease-covid-19-company-decided-to-pause-the-recruitment-of-global-phase-iii-clinical-study-for-3-months-and-will-restart-recruitment-when-epidemic/ 2024-04-26T14:36:30+08:00 https://www.obipharma.com/announcement/updates-on-companys-negotiable-securities-for-investors-information/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/announcement-on-change-of-accountant-due-to-internal-adjustment-of-accounting-firm/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/the-board-of-directors-resolved-to-hold-2020-annual-general-meeting/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/the-board-of-directors-have-resolved-not-to-distribute-dividends-for-2019/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/board-of-directors-approved-the-companys-2019-financial-statement/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/clarification-on-news-article-by-economy-daily-news/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-investor-conference-hosted-by-masterlink-securities-2/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/announcement-of-the-u-s-fda-approval-on-orphan-drug-designation-of-globo-h-antibody-drug-conjugate-obi-999-targeting-gastric-cancer/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-the-38th-annual-j-p-morgan-healthcare-conference/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/announcement-of-the-u-s-fda-approval-on-orphan-drug-designation-of-globo-h-antibody-drug-conjugate-obi-999-targeting-pancreatic-cancer/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/supplementary-statement-regarding-the-news-article-by-economy-daily-news/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/board-of-directors-agreed-subsidiary-obi-pharma-shanghai-limited-to-implement-partial-intellectual-property-rights-of-headquarter-rights-in-china/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/announcement-on-change-of-general-manager/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/clarification-on-news-articles/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/explanation-on-news-article-by-economy-daily-news/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-investor-conference-hosted-by-masterlink-securities/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/announcement-of-phase-ii-clinical-trial-result-for-ovarian-cancer-on-obi-and-mackay-memorial-hospital-cooperated-adagloxad-simolenin-obi-822/ 2024-04-26T14:36:31+08:00 https://www.obipharma.com/announcement/announcement-on-change-of-research-and-development-officer/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/obi-pharma-announces-u-s-fda-clearance-of-ind-application-for-a-phase-i-ii-study-of-its-antibody-drug-conjugate-adc-targeted-cancer-therapy-obi-999/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/board-of-directors-approved-the-change-of-financial-officer-and-acting-spokesperson/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/ind-phase-i-ii-human-clinical-trial-application-of-globo-h-antibody-drug-conjugate-obi-999-submission-to-fda/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/announcement-on-change-of-financial-officer-and-acting-spokesperson/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/subsidiary-ap-biosciences-and-tasly-biopharmaceuticals-signed-cooperative-development-and-authorized-agreement-of-new-antibody-drug/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/announcement-on-the-change-of-spokesperson/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/announcement-of-new-ceo/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/announcement-of-3rd-audit-committee-members/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/announcement-of-4th-payroll-committee-members/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/taiwan-shilin-district-court-appeals-against-the-acquittal-of-mr-michael-chang-and-five-other-executivesinsider-trading-case/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/supplementary-statement-regarding-the-news-article-by-the-investor-and-other-news-media/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/announcement-of-the-status-of-implementation-of-the-commitments-during-the-up-listing-at-over-the-counter-market/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/companys-board-of-directors-nominated-michael-chang-to-serve-as-the-chairman-of-the-board/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/announcement-to-permit-competitive-conduct-by-officers/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/announcement-on-re-election-of-board-of-directors-at-the-2019-annual-general-meeting/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/announcement-of-resolution-items-from-2019-annual-general-meeting/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-internet-media-on-jun-212019/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/company-chairman-mr-michael-chang-and-other-five-executives-received-an-acquittal-for-insider-trading-case-by-taiwan-shilin-district-court/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/clarification-on-new-article-by-economy-daily-news-dated-jun-16-2019/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/obi-888-completes-phase-i-safety-evaluation-and-demonstrates-its-safety-and-tolerability-with-no-major-concerns/ 2024-04-26T14:36:32+08:00 https://www.obipharma.com/announcement/announcement-of-the-companys-cash-capital-increase-and-base-date/ 2024-04-26T14:36:33+08:00 https://www.obipharma.com/announcement/board-of-directors-of-the-company-waived-subscription-rights-exceeding-half-of-the-total-subscribable-shares-shares-to-be-subscribed-by-designated-persons/ 2024-04-26T14:36:33+08:00 https://www.obipharma.com/announcement/letter-received-from-national-medical-products-administration-nmpa-of-china-regarding-adagloxad-simolenin-obi-822-phase-iii-clinical-study-to-be-resubmitted-after-supplementation/ 2024-04-26T14:36:33+08:00 https://www.obipharma.com/announcement/supplementary-announcement-for-the-company-to-issue-ordinary-shares-through-rights-offering/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/supplementary-announcement-for-2019-annual-general-meeting/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/announcement-for-the-company-to-issue-ordinary-shares-through-rights-offering-and-bank-designated-for-collection-and-deposition/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/clearance-of-adagloxad-simolenin-obi-822-for-a-phase-iii-clinical-study-by-ministry-of-health-of-the-russian-federation/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/announcement-for-the-company-to-issue-ordinary-shares-through-rights-offering/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/announcement-of-capital-change-registration-for-the-treasury-share-retirement/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/the-board-of-directors-have-resolved-not-to-distribute-dividends-for-2018/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/the-board-of-directors-resolved-to-hold-2019-annual-general-meeting/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/change-of-accountant-due-to-internal-adjustment-of-the-accounting-firm/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/board-of-directors-approved-the-companys-2018-individual-and-consolidated-financial-statements/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/announcement-of-the-resolution-of-the-treasury-shares-and-the-establishment-of-the-base-date-for-capital-reduction-by-board-of-directors/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/clearance-of-adagloxad-simolenin-obi-822-for-a-phase-iii-clinical-study-by-ministry-of-health-of-ukraine/ 2024-04-26T14:36:34+08:00 https://www.obipharma.com/announcement/clarification-on-the-collaborative-publication-by-obi-pharma-inc-and-academia-sinica/ 2024-04-26T14:36:35+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-the-37th-annual-j-p-morgan-healthcare-conference/ 2024-04-26T14:36:35+08:00 https://www.obipharma.com/announcement/company-chairman-mr-michael-n-chang-not-guilty-for-the-prosecution-by-taiwan-shilin-district-court/ 2024-04-26T14:36:35+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-2019-investor-conference-hosted-by-yuanta/ 2024-04-26T14:36:35+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-the-citis-2018-global-healthcare-conference/ 2024-04-26T14:36:35+08:00 https://www.obipharma.com/announcement/announcement-of-the-resolution-of-the-board-of-directors-of-the-company-to-issue-common-shares-through-rights-offering/ 2024-04-26T14:36:35+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-the-2018-asia-pacific-healthcare-forum-hosted-by-goldman-sachs/ 2024-04-26T14:36:35+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-up-media-and-other-media-groups/ 2024-04-26T14:36:35+08:00 https://www.obipharma.com/announcement/obi-pharma-granted-fda-orphan-drug-designation-for-obi-888-for-the-treatment-of-pancreatic-cancer-2/ 2024-04-26T14:36:35+08:00 https://www.obipharma.com/announcement/department-of-health-doh-clearance-of-adagloxad-simolenin-obi-822-for-a-phase-iii-clinical-study-in-hong-kong/ 2024-04-26T14:36:36+08:00 https://www.obipharma.com/announcement/investigational-device-exemption-ide-for-the-development-of-obi-888-was-approved-by-the-us-food-and-drug-administration-fda-for-its-use-in-obi-888-phase-i-cohort-expansion-phase/ 2024-04-26T14:36:37+08:00 https://www.obipharma.com/announcement/clearance-of-adagloxad-simolenin-obi-822-for-a-phase-iii-clinical-study-in-the-united-states/ 2024-04-26T14:36:38+08:00 https://www.obipharma.com/announcement/obi-pharma-australia-pty-ltd-announces-the-clearance-of-adogloxad-simolenin-obi-822-for-a-phase-iii-clinical-study-in-australia/ 2024-04-26T14:36:38+08:00 https://www.obipharma.com/announcement/obi-received-notice-from-patent-attorneys-office-that-product-patent-for-obi-822-named-compound-and-compositions-of-carbohydrate-vaccine-and-uses-thereof-has-been-approved-by-taiwan-intelle/ 2024-04-26T14:36:39+08:00 https://www.obipharma.com/announcement/taiwan-fda-clearance-of-adagloxad-simolenin-obi-822-for-a-phase-iii-clinical-study/ 2024-04-26T14:36:39+08:00 https://www.obipharma.com/announcement/correction-on-previous-announcement-clarification-on-the-news-article-by-commercial-times-to-united-daily-news/ 2024-04-26T14:36:39+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-commercial-times-4/ 2024-04-26T14:36:39+08:00 https://www.obipharma.com/announcement/obi-pharma-granted-fda-orphan-drug-designation-for-obi-3424-for-the-treatment-of-acute-lymphoblastic-leukemia-all-2/ 2024-04-26T14:36:39+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-2018-industry-forum-hosted-by-masterlink-securities/ 2024-04-26T14:36:39+08:00 https://www.obipharma.com/announcement/obi-received-notice-from-patent-attorneys-office-that-product-patent-for-obi-3424-named-dna-alkylating-agents-has-been-approved-by-ip-australia/ 2024-04-26T14:36:39+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-commercial-times-3/ 2024-04-26T14:36:39+08:00 https://www.obipharma.com/announcement/investigational-device-exemption-ide-for-the-development-of-adagloxad-simolenin-obi-822-was-approved-by-the-us-food-and-drug-administration-fda-for-its-use-in-obi-822-phase-iii-clinical-trial/ 2024-04-26T14:36:39+08:00 https://www.obipharma.com/announcement/obi-pharma-granted-fda-orphan-drug-designation-for-obi-3424-for-the-treatment-of-hepatocellular-carcinoma-hcc-2/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-on-the-board-resolution-at-annual-general-meeting-2018/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/amendment-on-the-announcement-for-2018-annual-general-meeting-discussion-notes/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/the-board-of-directors-of-the-company-resolved-to-request-the-shareholders-to-authorize-the-board-of-directors-to-handle-cash-increase-of-common-shares-to-issue-overseas-depository-receipts/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/the-board-of-directors-of-the-company-resolved-to-request-the-shareholders-to-authorize-the-board-of-directors-to-handle-private-placement-of-common-shares-at-the-annual-general-meeting/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/amendment-on-the-announcement-for-2018-annual-general-meeting/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-of-change-of-accountant-due-to-internal-adjustment-of-the-accounting-firm/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-based-on-the-procedures-for-acquisition-or-disposal-of-assets/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/fda-clearance-of-obi-3424-ind-application-for-a-phase-i-ii-study-targeting-akr1c3-solid-tumors/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-credit-suisse-asian-investment-conference/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-on-the-change-of-chief-financial-officer/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharmas-board-of-directors-approves-the-announcement-of-the-companys-2017-individual-and-consolidated-financial-statements/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/the-board-of-directors-have-resolved-2017-not-to-distribute-dividends/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/the-board-of-directors-resolved-to-hold-2018-annual-general-meeting/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-articles-by-commercial-times-united-daily-etc/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/fda-clearance-of-ind-application-for-a-phase-1-study-of-a-monoclonal-antibody-cancer-immunotherapy-obi-888/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/shilin-district-court-deny-obis-request-to-submit-the-case-for-trial/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-the-investor-conference-on-new-drug-development-hosted-by-masterlink-securities/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/capital-increase-for-new-shares-to-transfer-to-ap-biosciences-inc/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-the-36th-j-p-morgan-annual-healthcare-conference/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-citis-2017-global-healthcare-conference/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-to-attend-the-2017-asia-pacific-healthcare-forum-hosted-by-goldman-sachs/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/sfipc-and-obi-jointly-agreed-to-withdraw-the-proceedings-on-civil-case-regarding-the-dismissal-of-the-chairman-of-the-company/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-plans-to-issue-new-shares-in-exchange-for-the-ap-biosciences-inc-shares-owned-by-abprotixinc-subject-to-regulatory-approval/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-on-change-of-the-accounting-officer/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/uspto-approved-the-patent-application-for-obi-888-antibodies-pharmaceutical-compositions-and-uses-thereof/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/contract-signing-with-pharmacore-for-the-contract-manufacturing-of-obi-858/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-on-change-of-the-acting-spokesperson/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-on-change-of-the-head-of-finance-and-accounting/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-received-a-civil-complaint-from-taiwan-shilin-district-court/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-china-times/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-commercial-times-2/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/important-resolutions-of-agm-2017/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/supplemental-information-on-the-approved-application-of-phase-iii-clinical-trial-of-obi-822-the-novel-breast-cancer-drug-in-china-us-and-the-eu/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-announces-acquisition-of-the-novel-first-in-class-anti-cancer-drug-obi-3424-from-threshold-pharmaceuticals-to-be-developed-as-potential-anti-cancer-therapy-for-cancers-with-high-akr1c3/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-of-explanation-on-the-first-instance-judgment-of-the-civil-action-between-the-company-against-next-magazine/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-of-explanation-on-the-companys-criminal-lawsuit-against-next-magazine/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-833-the-cancer-therapeutic-vaccine-has-met-the-primary-safety-indicators-in-phase-i-clinical-trial-for-us-and-taiwan/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/the-board-of-directors-have-resolved-not-to-distribute-dividends/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-by-the-companys-board-of-directors-to-convene-the-2016-annual-general-shareholders-meeting/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharmas-board-of-directors-approves-the-announcement-of-the-companys-2016-individual-and-consolidated-financial-statements/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/supplemental-information-obi-822-was-approved-to-enter-a-phase-iii-clinical-trial-by-the-china-food-and-drug-administration-cfda/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-822-was-approved-to-enter-a-phase-iii-clinical-trial-by-the-china-food-and-drug-administration-cfda/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-announces-the-change-of-chief-operating-officer/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-commercial-times/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-united-daily-news-e-paper/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-economic-daily-news-2/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/press-release-by-the-shihlin-district-prosecutors-office-taiwan/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-of-the-signing-of-a-non-binding-letter-of-intent-for-obi-pharma-inc-to-issue-new-shares-to-abprotix-inc-in-exchange-for-up-to-70-stake-in-ap-biosciences/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-economic-daily-news/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-granted-patent-approval-for-its-2nd-generation-active-immunotherapy-treatment-by-taiwan-and-australia/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/clarification-on-the-news-article-by-economic-daily-news-e-paper/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/to-clarify-the-media-report-3/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/additional-charges-on-next-digital-ltd-hong-kong/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/the-company-was-invited-to-participate-in-17th-annual-asian-technology-conference-organized-by-credit-suisse/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/to-clarify-the-media-report-4/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-announces-the-change-of-vp-chief-medical-officer/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/to-clarify-the-media-report/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/important-resolutions-of-2016-annual-general-shareholders-meeting/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/the-re-election-of-directors-at-2016-annual-general-shareholders-meeting/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-s-2016-annual-general-meeting-has-approved-to-release-the-newly-elected-director-from-non-competition-restriction/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-announces-the-re-appointment-of-mr-michael-chang-as-the-chairman-of-the-company/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/the-company-was-invited-to-participate-in-the-overseas-ndr-non-deal-roadshow-organized-by-credit-suisse-and-reported-the-study-results-presented-in-the-2016-asco/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/obi-pharma-inc-will-attend-cathay-securities-conference-on-june-16th/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/to-correct-the-companys-investor-conference-presentation-content-on-june-5-2016/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/to-clarify-the-media-report-2/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/the-company-will-publish-the-clinical-study-data-of-the-innovation-research-of-obi-822-obi-821-for-metastatic-breast-cancer-patients-at-the-annual-meeting-of-2016-asco/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/announcement-of-the-company-holding-investor-presentation-and-significant-post-press-conference/ 2024-04-26T14:36:40+08:00 https://www.obipharma.com/announcement/company-will-hold-the-investor-conference/ 2024-04-26T14:36:41+08:00 https://www.obipharma.com/announcement/the-company-states-the-medias-reports-on-the-related-matters-of-american-society-of-clinical-oncology-asco/ 2024-04-26T14:36:41+08:00 https://www.obipharma.com/announcement/media-reports-that-michael-chang-the-chairman-of-the-company-amy-huang-the-general-manager-and-the-staffs-six-people-in-total-were-guaranteed-pending-summons-for-alleged-insider-trading/ 2024-04-26T14:36:41+08:00 https://www.obipharma.com/announcement/publication-of-the-breast-cancer-study-abstract-to-be-presented-at-asco-2016/ 2024-04-26T14:36:41+08:00 https://www.obipharma.com/announcement/board-intentions-to-apply-for-long-term-fund-raising-plan/ 2024-04-26T14:36:41+08:00 https://www.obipharma.com/announcement/supplementary-notice-on-a-company-board-resolution-for-the-upcoming-2016-annual-shareholders-meeting/ 2024-04-26T14:36:41+08:00 https://www.obipharma.com/announcement/company-reports-outsider-suspected-of-rumor-mongering-intended-to-manipulate-companys-stock-and-plans-to-take-legal-action-against-next-magazine/ 2024-04-26T14:36:41+08:00 https://www.obipharma.com/announcement/obi-pharma-announces-the-end-of-the-implementation-for-its-first-treasury-share-buyback-program/ 2024-04-26T14:36:41+08:00 https://www.obipharma.com/member/wei-han-lee-ph-d/ 2026-03-24T16:35:00+08:00 https://www.obipharma.com/member/jukka-muhonen/ 2026-01-08T17:22:55+08:00 https://www.obipharma.com/member/chen-tai-tsang-%e5%8d%9a%e5%a3%ab/ 2025-08-07T08:34:03+08:00 https://www.obipharma.com/member/david-huang-ph-d/ 2026-01-07T13:46:32+08:00 https://www.obipharma.com/member/ya-chi-chen/ 2025-06-09T11:18:33+08:00 https://www.obipharma.com/member/tod-lauerman/ 2024-12-19T13:55:19+08:00 https://www.obipharma.com/member/wade-liu/ 2024-11-27T16:12:00+08:00 https://www.obipharma.com/member/colin-kao/ 2025-06-09T18:31:10+08:00 https://www.obipharma.com/member/xiao-michelle-meng/ 2024-11-19T11:43:02+08:00 https://www.obipharma.com/member/chin-ting-chiu/ 2024-06-03T16:23:18+08:00 https://www.obipharma.com/member/ming-chin-chen-ph-d/ 2024-06-03T16:23:22+08:00 https://www.obipharma.com/member/howard-s-lee-ph-d/ 2024-06-03T16:20:49+08:00 https://www.obipharma.com/member/wan-fang-ting/ 2024-06-03T16:20:20+08:00 https://www.obipharma.com/member/tamon-tseng-ll-m/ 2024-06-04T16:56:42+08:00 https://www.obipharma.com/member/kung-yee-liang-ph-d/ 2024-11-19T16:14:01+08:00 https://www.obipharma.com/member/steven-innaimo/ 2026-04-01T16:52:21+08:00 https://www.obipharma.com/member/christa-maurer/ 2024-11-19T11:55:27+08:00 https://www.obipharma.com/member/dong-xu/ 2025-06-06T16:59:51+08:00 https://www.obipharma.com/member/kevin-p-poulos/ 2024-11-19T14:25:45+08:00 https://www.obipharma.com/member/wayne-saville/ 2024-11-19T13:39:58+08:00 https://www.obipharma.com/member/ming-tain-lai/ 2024-11-19T16:08:10+08:00 https://www.obipharma.com/member/heidi-wang/ 2026-03-25T09:36:55+08:00